Drug Information

Drug General Information
Drug ID
D0C9NJ
Former ID
DCL000235
Drug Name
STA-5326
Synonyms
Apilimod; STA 5326; STA5326; N-[(3-methylphenyl)methylideneamino]-6-morpholin-4-yl-2-(2-pyridin-2-ylethoxy)pyrimidin-4-amine
Drug Type
Small molecular drug
Indication Crohn's disease; Moderate-to-severe rheumatoid arthritis [ICD9: 555, 714; ICD10:K50, M05-M06] Phase 2 [528277], [536054]
Company
Synta Pharma
Structure
Download
2D MOL

3D MOL
Formula
C23H26N6O2
Canonical SMILES
CC1=CC=CC(=C1)C=NNC2=NC(=NC(=C2)N3CCOCC3)OCCC4=CC=CC=N4
InChI
1S/C23H26N6O2/c1-18-5-4-6-19(15-18)17-25-28-21-16-22(29-10-13-30-14-11-29)27-23(26-21)31-12-8-20-7-2-3-9-24-20/h2-7,9,15-17H,8,10-14H2,1H3,(H,26,27,28)/b25-17+
InChIKey
HSKAZIJJKRAJAV-KOEQRZSOSA-N
CAS Number
CAS 870087-36-8
PubChem Compound ID
10173277
PubChem Substance ID
15167343, 22569595, 40157426, 50086921, 79966990, 126671650, 135196128, 135367566, 135697660, 137263434, 143011933, 152049021, 152344401, 162254889, 196408551, 198972105, 210275117, 210280756, 223673270, 226751034, 252160088
Target and Pathway
Target(s) Interleukin-12 Target Info Inhibitor [536292], [536876]
KEGG Pathway Cytokine-cytokine receptor interaction
Toll-like receptor signaling pathway
RIG-I-like receptor signaling pathway
Jak-STAT signaling pathway
Type I diabetes mellitus
Pertussis
Legionellosis
Leishmaniasis
Chagas disease (American trypanosomiasis)
African trypanosomiasis
Malaria
Toxoplasmosis
Amoebiasis
Tuberculosis
Measles
Influenza A
Herpes simplex infection
Inflammatory bowel disease (IBD)
Allograft rejection
Pathway Interaction Database IL27-mediated signaling events
IL12-mediated signaling events
WikiPathways Toll-like receptor signaling pathway
Aryl Hydrocarbon Receptor Pathway
Allograft Rejection
Regulation of toll-like receptor signaling pathway
References
Ref 528277A phase 1/2A trial of STA 5326, an oral interleukin-12/23 inhibitor, in patients with active moderate to severe Crohn's disease. Inflamm Bowel Dis. 2006 Jul;12(7):558-65.
Ref 536054Emerging drugs for moderate-to-severe psoriasis. Expert Opin Emerg Drugs. 2005 Feb;10(1):35-52.
Ref 536292Selective abrogation of Th1 response by STA-5326, a potent IL-12/IL-23 inhibitor. Blood. 2007 Feb 1;109(3):1156-64. Epub 2006 Oct 19.
Ref 536876Therapeutic effect of the potent IL-12/IL-23 inhibitor STA-5326 on experimental autoimmune uveoretinitis. Arthritis Res Ther. 2008;10(5):R122. Epub 2008 Oct 13.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.